Tranilast is a pharmaceutical drug used to treat allergies and asthma. The spelling of this word is based on its chemical structure, which includes the prefix "tran-" and the suffix "-last." The IPA phonetic transcription of the word is /trænɪlæst/, with stress on the second syllable. The "tr" sound is pronounced as a voiceless alveolar stop sound, while the "æ" sound is pronounced as an open front unrounded vowel. The final "t" is pronounced as a voiceless alveolar stop sound.
Tranilast is a drug that belongs to the class of medications known as anti-allergics. It is primarily used to treat or manage allergic disorders, such as asthma, hay fever, and numerous other allergic conditions. Tranilast works by inhibiting the release of certain inflammatory substances, including histamine and leukotrienes, which are responsible for causing allergy symptoms.
The drug's mechanism of action involves suppressing the activation and migration of inflammatory cells, such as eosinophils and mast cells. By doing so, it helps to alleviate various allergic reactions, including bronchial constriction, nasal congestion, itching, and inflammation.
Tranilast is available in oral tablet form and is typically taken two to four times a day, as directed by a healthcare professional. The dosage may vary depending on the specific condition being treated, the severity of symptoms, and the patient's individual response to the medication. It is essential to follow the prescribed dosage and duration of treatment to achieve the desired therapeutic outcomes.
Although generally well-tolerated, tranilast may cause certain side effects, including drowsiness, dizziness, gastrointestinal disturbances, and skin rashes. Patients should notify their healthcare provider if any adverse reactions occur or persist.
Overall, tranilast is a medication used for managing allergic disorders by reducing inflammation and preventing the release of inflammatory substances, thereby providing relief from symptoms associated with allergies.
The word "tranilast" is derived from a combination of two parts: "trani" and "last".
The "trani" part comes from the chemical name 2-(3,4-dimethoxyphenyl)-3-methyl-1-(3-pyridinylmethyl)-1H-pyrrole. This compound was initially developed and branded as Rizaben in Japan by the pharmaceutical company Kissei. The name "trani" is a short form of the chemical compound's name.
The "last" part of the word is a common suffix found in many pharmaceutical drug names. It is derived from the English word "mast", which means to keep or sustain. The suffix "last" is often used to convey the idea of a drug that can provide long-lasting effects or positive outcomes.